CTLA4 and Autoimmunity: Interestingly, the main complications during the treatment of patients with PD-1/PDL-1 blocking antibodies and with Treg-reducing CTLA-4 antibodies [28,29] are autoimmune disorders that are frequently manifested in the gut [51].